Worth reading
50Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Neutral
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Who is moving to which position
Resolved 14 May 2026Incoming appointee
2 itemsScheduled Appointment DateScheduled for 26 June 2026 (to be formally decided by resolutions of the 56th Annual General Meeting of Shareholders and the Board of Directors meeting scheduled for the same day)
Keiji Matoba (的場 敬司)
Previous positionExecutive Officer, General Manager of the Sales Division
New positionDirector, Sales; General Manager, Sales Division
生年月日 15 November 1969入社年 2003所有株式数 Not disclosed
Atsuko Ochiai (落合 敦子)
Previous positionAdvisor to the Company (current)
New positionOutside Director (Director serving as an Audit and Supervisory Committee Member)
生年月日 9 November 1974入社年 Not disclosed所有株式数 0 shares (as of today)
Departing officer
1 itemDate of departureScheduled for 26 June 2026
Mitsuru Takita (滝田 充)Next role stated
Former PositionDirector, Sales
New positionExecutive Officer, Medical and Life Sciences Business; Representative Director and President, 株式会社朝日フロントメディック
“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Whether the incumbent will remain in office (whether they will retain their position)
He will not remain on the Board of Directors, but will remain as an executive officer and as representative director and president of the subsidiary.
Directors after the change8Number
Filing as an independent officerThe Company plans to register Atsuko Ochiai (落合 敦子) with the Tokyo Stock Exchange as an independent officer.
Shareholders’ meeting approvalYes. The Company plans to submit a proposal for the election of director candidates to the 56th Annual General Meeting of Shareholders, scheduled to be held on 26 June 2026.
Reasons for appointment
To utilize her extensive experience and deep knowledge in financial institutions, as well as her experience and knowledge in ESG, CSR and the promotion of women's advancement, in audits and supervision aimed at achieving the Company's medium-term management plan.
Independent officers are outside officers registered with the exchange as having no conflict of interest with general shareholders.
| Item | Details |
|---|---|
| Resolution date | 14 May 2026 |
| Scheduled Appointment Date | Scheduled for 26 June 2026 (to be formally decided by resolutions of the 56th Annual General Meeting of Shareholders and the Board of Directors meeting scheduled for the same day) |
| Date of departure | Scheduled for 26 June 2026 |
| Name of appointee | Keiji Matoba (的場 敬司), Atsuko Ochiai (落合 敦子) |
| Appointee's new position | Director, Sales; General Manager, Sales Division, Outside Director (Director serving as an Audit and Supervisory Committee Member) |
| Appointee's previous position | Executive Officer, General Manager of the Sales Division, Advisor to the Company (current) |
| Appointee's date of birth | 15 November 1969, 9 November 1974 |
| Year the appointee joined the Company | 2003, Not disclosed |
| Number of shares held by the appointee | Not disclosed, 0 shares (as of today) |
| Name of departing officer | Mitsuru Takita (滝田 充) |
| Former position of departing officer | Director, Sales |
| New position of departing officer | Executive Officer, Medical and Life Sciences Business; Representative Director and President, 株式会社朝日フロントメディック |
| Whether the incumbent will remain in office | He will not remain on the Board of Directors, but will remain as an executive officer and as representative director and president of the subsidiary. |
| Reasons for appointment | To utilize her extensive experience and deep knowledge in financial institutions, as well as her experience and knowledge in ESG, CSR and the promotion of women's advancement, in audits and supervision aimed at achieving the Company's medium-term management plan. |
| Number of directors after the change | 8, including 3 outside directors |
| Filing as an independent officer | The Company plans to register Atsuko Ochiai (落合 敦子) with the Tokyo Stock Exchange as an independent officer. |
| Subject to Approval by the General Meeting of Shareholders | Yes. The Company plans to submit a proposal for the election of director candidates to the 56th Annual General Meeting of Shareholders, scheduled to be held on 26 June 2026. |
Items this document does not state (4)
Reason for departureReason for changeDetails of organizational changesChange in Corporate Governance Structure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company stated that Atsuko Ochiai (落合 敦子)'s extensive experience and deep knowledge in financial institutions, as well as her experience and knowledge in ESG, CSR and the promotion of women's advancement, will be utilized in audits and supervision aimed at achieving the Company's medium-term management plan. No reasons were provided for the other changes.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.